Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$74.55 USD
+0.53 (0.72%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $74.61 +0.06 (0.08%) 6:06 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RDY 74.55 +0.53(0.72%)
Will RDY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDY
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
Other News for RDY
RDY Crosses Above Average Analyst Target
Dr. Reddy’s Forges Nutraceuticals JV; Leadership Changes
Nestlé and Dr. Reddy’s Forge Nutraceuticals JV
Dr. Reddy’s Announces Urgent Medication Recall
Dr. Reddy’s Faces USFDA Hurdle for Biosimilar